TARSUS PHARMACEUTICALS INC's ticker is TARS and the CUSIP is 87650L103. A total of 45 filers reported holding TARSUS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $40,199,294 | -1.7% | 2,262,200 | 0.0% | 4.40% | +56.1% |
| Q2 2023 | $40,877,954 | +43.8% | 2,262,200 | 0.0% | 2.82% | +43.0% |
| Q1 2023 | $28,435,854 | +85643.1% | 2,262,200 | 0.0% | 1.97% | -48.3% |
| Q4 2022 | $33,164 | -99.9% | 2,262,200 | 0.0% | 3.82% | -10.7% |
| Q3 2022 | $38,729,000 | +14.7% | 2,262,200 | -2.2% | 4.28% | +26.1% |
| Q2 2022 | $33,761,000 | -32.8% | 2,312,368 | -22.6% | 3.39% | -2.0% |
| Q1 2022 | $50,247,000 | -25.2% | 2,987,331 | 0.0% | 3.46% | -14.6% |
| Q4 2021 | $67,215,000 | +4.4% | 2,987,331 | 0.0% | 4.05% | +40.2% |
| Q3 2021 | $64,377,000 | -25.6% | 2,987,331 | 0.0% | 2.89% | -22.9% |
| Q2 2021 | $86,573,000 | -17.2% | 2,987,331 | -7.9% | 3.75% | +2.0% |
| Q1 2021 | $104,587,000 | -22.0% | 3,245,035 | 0.0% | 3.68% | -38.6% |
| Q4 2020 | $134,117,000 | – | 3,245,035 | – | 5.98% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 2,084,370 | $30,432,000 | 4.62% |
| Vivo Capital, LLC | 2,312,368 | $33,761,000 | 3.39% |
| Frazier Life Sciences Management, L.P. | 1,787,527 | $26,098,000 | 2.46% |
| Cormorant Asset Management, LP | 1,875,000 | $27,375,000 | 2.07% |
| Sands Capital Ventures, LLC | 260,000 | $3,796,000 | 1.04% |
| Ghost Tree Capital, LLC | 120,000 | $1,752,000 | 0.91% |
| RTW INVESTMENTS, LP | 2,013,601 | $29,399,000 | 0.76% |
| COWEN AND COMPANY, LLC | 534,524 | $7,804,000 | 0.75% |
| Perceptive Advisors | 1,296,416 | $18,927,000 | 0.59% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,324,214 | $19,334,000 | 0.40% |